EDGC Issues 224.8M Shares via Debt-to-Equity at 76% Discount, Diluting Existing Shareholders by 62%
EDGC issues 224,797,110 new shares (approximately 162% of current outstanding) via third-party allotment to creditors as debt-to-equity conversion under the approved rehabilitation plan.
The issuance price is KRW 100 per share, a 76% discount to the current price of KRW 415, an inevitable step for debt repayment under the rehabilitation proceedings.
Total outstanding shares surge from 138,493,951 to 363,291,061, severely diluting existing shareholders' stakes.
This capital increase involves no cash inflow; it converts debt into equity with court approval.
A share consolidation is also scheduled on the same date, but it is insufficient to offset the massive dilution from the new shares.
[AI Comprehensive Analysis]This debt-to-equity conversion is essential for EDGC's financial restructuring and survival, but it imposes extreme dilution risk on existing shareholders. The stock price is likely to plummet after the new shares are listed, and investors must be cautious about potential control changes and further capital erosion.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)
Company: Eone Diagnomics Genome Center (245620)
Submission: Eone Diagnomics Genome Center Co., Ltd.